Table 3.
Top significant canonical pathways differentially regulated between FCRx and SIS
| Ingenuity Canonical Pathways | Present Molecules (%) | Downregulated | Upregulated | P Value |
|---|---|---|---|---|
| B cell receptor signaling | 25/190 (13.2) | 4 | 21 | <0.001 |
| Protein kinase A signaling | 41/396 (10.3) | 16 | 25 | <0.001 |
| iNOS signaling | 9/45 (20) | 1 | 8 | 0.002 |
| SAPK/JNK signaling | 15/104 (14.5) | 6 | 9 | 0.002 |
| Mouse embryonic stem cell pluripotency | 15/106 (14.1) | 3 | 12 | 0.002 |
| 4–1BB signaling in T lymphocytes | 7/32 (21.9) | 1 | 6 | 0.003 |
| CD27 signaling in lymphocytes | 9/53 (17) | 3 | 6 | 0.005 |
| LPS/IL-1–mediated inhibition of RXR function | 23/221 (10.4) | 15 | 8 | 0.01 |
| Dopamine-DARPP32 feedback in cAMP signaling | 18/163 (11) | 7 | 11 | 0.01 |
| IL-22 signaling | 5/24 (20.8) | 0 | 5 | 0.01 |
Present molecules for each canonical pathway are broken down as downregulated and upregulated. Representative percentages of present versus total molecules per canonical pathways are shown between parentheses. iNOS, inducible nitric oxide synthase; SAPK, stress-activated protein kinases; JNK, jun amino-terminal kinases.